Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1115 for:    patricia
Previous Study | Return to List | Next Study

Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02448420
Recruitment Status : Recruiting
First Posted : May 19, 2015
Last Update Posted : July 18, 2019
Sponsor:
Information provided by (Responsible Party):
SOLTI Breast Cancer Research Group

Brief Summary:

PATRICIA is a phase II, open-label, multicentre, Simon's two-stage-design study of the combination of palbociclib plus trastuzumab, with or without letrozole, in post-menopausal patients with HER2-positive locally advanced or metastatic breast cancer (MBC) who have received chemotherapy and treatment with trastuzumab for their metastatic disease. Cohorts A, B1 and B2 based on their HR status and treatment allocation were planned. The aim of the PATRICIA study is to test the hypothesis that the addition of Palbociclib to standard therapy is well tolerated and can provide a benefit in progression-free survival.

Based on interim results from this trial that support the benefit of CDK4 / 6 inhibition in luminal disease, two additional cohorts will be included.


Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer Drug: Palbociclib Drug: Trastuzumab Drug: Endocrine therapy Drug: Chemotherapy Drug: Antibody-Drug Conjugates Phase 2

Detailed Description:

After the amendment of PATRICIA study, two additional cohorts will be included:

  • Cohort C1: will include patients with OR+, HER2 positive, Luminal intrinsic subtype determined by PAM50 who will receive trastuzumab + palbociclib + endocrine therapy (ET)
  • Cohort C2: will include patients with OR+, HER2 positive, Luminal intrinsic subtype determined by PAM50 who will receive treatment of physician's choice.

When the recruitment of those cohorts C begins, the recruitment in cohorts A and B will be closed.

For cohorts C, an adaptive design will be applied to compare arms of treatment in patients with Luminal subtype locally advanced or metastatic breast cancer (MBC).

All patients in those cohorts will have histologically- confirmed HR+/HER2-positive and PAM50-confirmed Luminal intrinsic subtype breast adenocarcinoma, and must have received at least 1 (and no more than 4) previous lines of anti-HER2 regimens for locally advanced disease or MBC (including prior treatment with a taxane, trastuzumab and Antibody-Drug conjugate).

Stratification factors will include number of previous regimens for advanced breast cancer (one and two vs three and four) and presence of visceral disease (yes vs no).

Treatment in all cohorts will be administered until progression, unacceptable toxicity, patient consent withdrawal, or death 516 patients will be screened and a total of 232 patients will be included. The inclusion period will be divided in two phases. During phase I it is planned to include 60 patients in 24 months; considering early stopping rule according to SF rate. During phase II, the trial will continue until the final evaluable number of patients are included.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 232 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Palbociclib in Combination With Trastuzumab and Endocrine Therapy in Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer (PATRICIA II)
Actual Study Start Date : July 2015
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Arm C1: Palbociclib, trastuzumab and endocrine therapy

HR positive, HER2 positive, Luminal intrinsic subtype determined by PAM50 who will receive trastuzumab + palbociclib + endocrine therapy

Trastuzumab or biosimilar: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.

Palbociclib:oral, 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles.

Endocrine therapy: either an Aromatase Inhibitor, Fulvestrant or Tamoxifen.

Drug: Palbociclib
Oral dose 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles.
Other Name: Ibrance

Drug: Trastuzumab
Loading dose of 8mg/kg intravenous (iv) followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.
Other Name: Herceptin, trastuzumab biosimilar

Drug: Endocrine therapy
Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen
Other Name: ET

Active Comparator: Arm C2: Treatment based of physician's choice
HR positive, HER2 positive, Luminal intrinsic subtype determined by PAM50 who will receive Treatment based of physician's choice from the following options: TDM1 or chemotherapy (gemcitabine, vinorelbine, capecitabine, eribulin or a taxane) in combination with trastuzumab.
Drug: Trastuzumab
Loading dose of 8mg/kg intravenous (iv) followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.
Other Name: Herceptin, trastuzumab biosimilar

Drug: Chemotherapy
Gemcitabine, vinorelbine, capecitabine, eribulin or a taxane
Other Name: CT

Drug: Antibody-Drug Conjugates
3.6 mg/kg iv every 3 weeks
Other Name: Trastuzumab emtansine (TDM-1)




Primary Outcome Measures :
  1. Progression-Free Survival (PFS)as Assessed by the Investigator [ Time Frame: From randomization date to date of first documentation of progression or death [ Time Frame: From randomization date to date of first documentation of progression or death , whichever came first, assessed up to 5 years ]
    This will be defined as the proportion of patients alive and without progression (according to RECIST v1.1 criteria)


Secondary Outcome Measures :
  1. Rate of Disease control rate (DCR) in both treatment arms [ Time Frame: up to 5 years ]
    Number of patients with objective response (complete or partial) or stable disease according to RECIST 1.1 criteria for at least 8 weeks.

  2. Rate of Overall tumour objective response rate (ORR) in both treatment arms. [ Time Frame: up to 5 years ]
    Number of patients who achieve complete or partial response according to RECIST 1.1 criteria during treatment.

  3. Safety profile in both treatment arms: Percentage of Participants with Adverse Events [ Time Frame: up to 5 years ]
    Measurements used to assess the safety profile will include adverse events of any grade, grade 3 and 4 adverse events, withdrawals due to adverse events and dose reductions due to adverse events. CTCAE v.4.03 will be used to evaluate AE grade.

  4. 12-month Overall Survival in both treatment arms. [ Time Frame: up to 5 years ]
    Measured as time between treatment start and all-cause death.

  5. Change From Baseline Between Treatment Comparison in Functional Assessment of Cancer Therapy FACT-B to assess patient reported breast cancer specific health related quality of life (HRQOL) and general health status in both treatment arms. [ Time Frame: From the date of randomization up to 5 years ]
    The FACT-B consists of the Functional Assessment of Cancer Therapy-General (FACT-G) (27-items) and a breast-specific module: a 10-item instrument designed to assess patient concernsrelating to BC. The FACT-G is a 27-item compilation of general questions divided into 4 domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, and Functional Well-Being. Patients are asked to respond to a Likert scale where 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much.

  6. Change From Baseline Between Treatment Comparison in Euroqol-5D (EQ-5D) to assess patient reported breast cancer specific health related quality of life (HRQOL) and general health status in both treatment arms. [ Time Frame: From the date of randomization up to 5 years ]
    The EuroQol EQ-5D is designed to assess health status in terms of a single index value or utility score. It contains 5 descriptors of current health state (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with each dimension having 5 levels of function (1=no problem, 2=slight problem, 3=moderate problem, 4=severe problem, and 5=unable/extreme). The scores on the 5 descriptors are summarized to create a single summary score. The EQ-5D also includes a visual analog scale (VAS), in which the patients self-rate their overall health status on a scale from 0 (worst imaginable) to 100 (best imaginable).

  7. To investigate baseline tumor and blood biomarkers as predictors of response or resistance to the study treatment. [ Time Frame: up to 5 years ]
    The codeset of 110 genes include the 50 genes assessed in the PAM50 intrinsic subtype predictor platform and the expression of 60 additional genes covering a significant biological variation of gene signatures relevant in breast cancer. Peripheral blood samples will be collected, and plasma extracted for circulating tumoral DNA (ctDNA) determination.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Written signed Informed Consent for all study procedures in accordance with the local administrative requirements prior to starting the protocol-specific procedures.
  2. Male or female patients. Premenopausal or postmenopausal women.
  3. Age 18 years or older.
  4. ECOG performance status 0 to 2 (Appendix 1).
  5. Invasive HER2 positive breast cancer, according to the central laboratory, defined according to ASCO/CAP criteria (Wolff et al. Arch Pathol Lab Med 2018;)
  6. Hormone receptor positive (HR+), determined locally according to ASCO/CAP guidelines; OR or PgR considered positive in case of ≥1% of cell nuclei positive.
  7. Centrally confirmed Luminal intrinsic subtype as per PAM50 analysis (i.e. Luminal A or Luminal B).
  8. Histologically confirmed adenocarcinoma of the breast, metastatic or locally advanced.

    1. Patients with locally advanced disease must have recurrent or progressive disease unsuitable for resection with curative intent. Patients with standard curative options available will not be eligible.
    2. In patients with bilateral breast cancer, HER2+ positivity must be demonstrated in both sites or in a metastatic biopsy.
  9. All patients must have received at least 1(maximum 4) previous lines of systemic treatment for metastatic or locally advanced disease, at least one of which must have included trastuzumab. Previous use of other anti-HER2 treatment, alone or in combination with chemotherapy, is permitted, including lapatinib, neratinib, pertuzumab or T-DM1. Previous use of any chemotherapy or hormone agent is permitted.
  10. Tumour tissue available for biomarker analysis, obtained from metastatic lesions (preferably) or from the primary tumour.
  11. Measurable or non-measurable (but evaluable) disease according to RECIST 1.1 criteria (Appendix 5).
  12. Adequate organ function, defined as:

    1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L.
    2. Haemoglobin (Hb) ≥9 g/dl (transfusion or use of EPO is permitted).
    3. Platelets > 100,000/mm3
    4. Creatinine ≤ 1.5 x normal value
    5. AST or ALT ≤ 2.5 x ULN (or ≤5 x ULN in case of liver metastasis)
    6. Alkaline phosphatase ≤2.5 x ULN. Alkaline phosphatase may be more than 2.5 x ULN only in the case of bone metastases, and AST and ALT less than 1.5 x ULN.
    7. Total bilirubin ≤1.5 mg/dl (higher bilirubin levels are permitted if the patient has Gilbert's syndrome).
  13. Baseline LVEF ≥50% measured using echocardiogram or equilibrium isotopic ventriculography (MUGA).
  14. Absence of psychological, family, sociological or geographical conditions that could potentially hinder compliance with the study protocol and follow-up schedule. These situations must be discussed with the patient before she is included in the study.
  15. If female of childbearing potential, must have a negative result of serum pregnancy test performed within 7 days prior to first dose of study treatment.
  16. Participants with a history of treated CNS metastases are eligible, provided they meet all of the following criteria:

    • Disease outside the CNS is present.
    • No evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study.
    • No history of intracranial hemorrhage or spinal cord hemorrhage.
    • Stable doses or no need of corticosteroids and anti-convulsants for symptomatic control
    • Minimum of 3 weeks between completion of CNS radiotherapy and Cycle 1 Day 1 of study treatment; and recovery from any significant (Grade ≥ 3) acute toxicity

Exclusion criteria

  1. Treatment with any investigational anticancer drug within 14 days of the start of study treatment.
  2. Patient has received more than 4 previous lines of treatment (anti-HER2 drug +/- chemotherapy) for metastatic breast cancer or locally advanced disease. Exclusively hormonal treatments will not be taken into account.
  3. Previous treatment with a cyclin-dependent kinase inhibitor.
  4. History of other malignant tumours in the past 5 years, with the exception of adequately treated in situ carcinoma of the cervix, non-melanoma carcinoma of the skin, uterine cancer in stage I or other malignant tumours with an expected curative outcome.
  5. Radiation therapy for metastases outside the brain carried out in the 21 days prior to inclusion in the study and/or patients who have received radiation to > 30% of the bone marrow.
  6. Symptomatic hypercalcemia requiring treatment with bisphosphonates in the 21 days prior to inclusion in the study. Biphosphonates will be permitted for the prevention of bone events.
  7. History of exposure to cumulative anthracycline doses greater than follows:

    1. Adriamycin > 400 mg/m2
    2. Epirubicin > 720 mg/m2
    3. Mitoxantrone > 120 mg/m2
    4. Idarubicin > 90 mg/m2
    5. If another anthracycline or more than one anthracycline has been used, the cumulative dose must not exceed the equivalent of 400 mg/m2 of adriamycin.
  8. Cardiopulmonary dysfunction, defined as:

    1. Uncontrolled hypertension (systolic > 150 mmHg and/or diastolic > 100 mmHg) despite optimum medical treatment.
    2. Angina pectoris or arrhythmia poorly controlled with optimum medical treatment.
    3. History of congestive heart failure NCI CTCAE version 4.0 grade ≥ 3 NYHA class ≥ 2.
    4. History of LVEF decrease to < 40% or symptomatic congestive heart failure during prior treatment with trastuzumab.
    5. Myocardial infarction within 6 months before randomisation.
    6. Resting dyspnoea due to complications of the malignant disease, requiring continuous oxygen therapy.
  9. Any other severe, uncontrolled disease (pulmonary, cardiac, metabolic, or haematological disorder, wound healing disorders, ulcers, bone fractures, infectious processes).
  10. Major surgery in the 28 days prior to randomisation or foreseeable during study treatment period.
  11. Infection with HIV or active Hepatitis B and/or Hepatitis C.
  12. History of trastuzumab intolerance, including grade 3-4 infusion reaction or hypersensitivity.
  13. Known hypersensitivity to any of the study drugs, including inactive ingredients.
  14. Inability, in the opinion of the investigator, to comply with the protocol requirements or any comorbidity that might hinder study follow-up, response evaluation or the informed consent process.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02448420


Contacts
Layout table for location contacts
Contact: Pamela Celiz, MD, PhD +34933436302 pamela.celiz@gruposolti.org
Contact: Jordi Canes +34933436302 jordi.canes@gruposolti.org

Locations
Layout table for location information
Spain
Hospital Clínic de Barcelona Recruiting
Barcelona, Spain
Principal Investigator: Aleix Prat, MD,PhD         
Hospital Universitario del Vall d' Hebron Recruiting
Barcelona, Spain
Principal Investigator: Javier Cortes, MD,PhD         
ICO Hospitalet Recruiting
Barcelona, Spain
Principal Investigator: Sonia Pernas, MD         
Consorcio Hospitalario Provincial de Castellón Recruiting
Castelló de la Plana, Spain
Principal Investigator: Eduardo Martinez, MD         
Centro Integral Oncológico Clara Campal (CIOCC) Recruiting
Madrid, Spain
Principal Investigator: Estela Vega, MD         
H. Severo Ochoa Recruiting
Madrid, Spain
Principal Investigator: María Jose Echarri, MD         
H. U Puerta de Hierro Recruiting
Madrid, Spain
Principal Investigator: Blanca Cantos         
Hospital Universitario Doce de Octubre Recruiting
Madrid, Spain
Principal Investigator: Eva Ciruelos, MD         
Hospital Universitario Ramon y Cajal Recruiting
Madrid, Spain
Principal Investigator: Noelia Martinez, MD         
Hospital Son Llatzer Recruiting
palma de Mallorca, Spain
Principal Investigator: Isabel Garau, MD         
Hospital Universitario Son Espases Recruiting
palma de Mallorca, Spain
Principal Investigator: Antonia Perello, MD         
Hospital Universitario Virgen del Rocio Recruiting
Sevilla, Spain
Principal Investigator: Alvaro Montaño, MD         
Hospital Universitario Sant Joan de Reus Recruiting
Tarragona, Spain
Principal Investigator: Mireia Mele, MD         
Hospital Clinico Universitario de Valencia Recruiting
Valencia, Spain
Principal Investigator: Begoña Bermejo, MD         
Sponsors and Collaborators
SOLTI Breast Cancer Research Group
Investigators
Layout table for investigator information
Principal Investigator: Eva Ciruelos, MD SOLTI Breast Cancer Research Group

Layout table for additonal information
Responsible Party: SOLTI Breast Cancer Research Group
ClinicalTrials.gov Identifier: NCT02448420     History of Changes
Other Study ID Numbers: SOLTI-1303
2014-005006-38 ( EudraCT Number )
First Posted: May 19, 2015    Key Record Dates
Last Update Posted: July 18, 2019
Last Verified: July 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Trastuzumab
Palbociclib
Antibodies
Immunoconjugates
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Immunological
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors
Enzyme Inhibitors